CLYM · Climb Bio, Inc.
$17.48
+0.46 (+2.70%)
At close · Aug 21
Market Cap
$977.57M
Shares
57.44M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.02
Open$17.16
Day$16.72–17.45
52W close$1.64–17.44
Avg vol 30d1.1M
Short int7.0M · 12.3% float · 6.8d
Short vol62%
Last earningsSep 3, 2026
DataAug 2021–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Sep 3, 2026
Scheduled
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+114%
above
Price vs 50-day avg
+29%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
97%
near high
Momentum
relative strength
1-month return
+33%
trailing
6-month return
+138%
trailing
YTD return
+326%
this year
Relative strength
+127%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+35% holders QoQ · +51 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.25% of float · ▲ +2.4% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
108 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
EPS growth
+42%
Y/Y
Free cash flow
$-54.5M
Balance sheet
$35.7M
net cash
Quant / Vol
risk profile
Volatility
96%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+114%
Bullish
Price vs 50-day avg
+29%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
97%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+35% holders QoQ · +51 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.25% of float · ▲ +2.4% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
108 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $17 · 97%
Range high $17
vs 200-day avg +114%
vs 50-day avg +29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLYM
this stock
Climb Bio, Inc.
|
$977.57M | +325.5% | — | — | 12.3% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLYM | +15.6% | +33.4% | +138.0% | +43.0% | +325.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +17.5% | +30.1% | +126.9% | +41.0% | +313.7% |
Key facts
CIK
1768446
CUSIP
28658R106
13F (30d)
107 filings
107 filers
Visit website
Investor relations